Managing ADC Toxicities Podcast

Podcast | English | 2024 | 50 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

Anti Drug Conjugates represent a new way of treating thoracic, breast, and gastrointestinal cancers. Despite recent successes, many ADCs failed during clinical development due to excessive toxicities and unfavorable risk-benefit profiles. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses ADCs and how clinicians can manage some of these toxicities.

Podcast Host:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA

Podcast Guests:

Benjamin Levy, MD, Thoracic Medical Oncologist and Clinical Director of Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Professor of Oncology at Johns Hopkins University School of Medicine, Washington, DC, USA
Paolo Tarantino, MD, Medical Oncologist, Dana-Farber Cancer Institute, Boston, MA, USA